Controlestril

Quick links to important sections

Controlestril

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Controlestril

Property Description
Active ingredient Medroxyprogesterone Acetate (MPA)
Form Oral Tablet, Injectable Suspension
Pharmacological class Progestational Agent / Synthetic Steroid
General purpose Hormonal Regulation, Endometrial Control
Origin Synthetic Derivative of Progesterone

Controlestril: Classification and Active Composition

Controlestril is a prescription-only medicine whose identity is fundamentally defined by its active ingredient, Medroxyprogesterone Acetate (MPA). This compound is classified as a progestin, or progestational agent, placing it within the category of endocrine therapy. MPA is a synthetic steroid, meaning it is chemically manufactured to mimic the function of the body's natural hormone, progesterone, while exhibiting enhanced potency and stability. This medicine is typically provided either as an oral tablet for administration by mouth or as a long-acting injectable suspension intended for intramuscular or subcutaneous injection.

Understanding Controlestril’s General Purpose

The overall purpose of Controlestril is to achieve hormonal regulation by providing a reliable source of the progestin compound. The fundamental physiological action of MPA is to activate the body's progesterone receptors, which serves to influence the menstrual cycle and the state of the uterine lining. The use of MPA includes helping to regulate menstrual periods in women who have not gone through menopause, underscoring its general utility for cycle stability. This action is clinically recognized for stabilizing the endometrium (uterine lining) and preventing its excessive thickening, which is essential for managing gynecological conditions and maintaining systemic hormonal balance.

Regulatory References

  1. Medroxyprogesterone: MedlinePlus Drug Information

What side effects are possible with Controlestril?

Possible Side Effects and Safety Information

The safety profile of Controlestril (Medroxyprogesterone Acetate) is defined by its officially documented adverse reactions, classified by frequency and system-organ class in regulatory sources.

Official Adverse Reactions and Frequencies

Adverse reactions are formally categorized based on the estimated frequency of occurrence:

Classification Examples of Documented Effects
Very Common (≥1/10) Headache, Nervousness.
Common (≥1/100 to <1/10) Depression, Dizziness, Insomnia, Nausea, Abdominal pain, Acne, Alopecia, Breast tenderness, Fatigue, Weight change, and changes in menstrual flow (e.g., irregular bleeding, spotting).
Uncommon (≥1/1,000 to <1/100) Somnolence, Hirsutism, Rash, Pyrexia, Edema.
Rare (<1/1,000) Thromboembolic disorders (e.g., Deep Vein Thrombosis, Pulmonary Embolism).
Frequency Not Known Anaphylactic/Anaphylactoid reactions.

These effects are formally grouped across system-organ classes, including Psychiatric, Nervous System, Gastrointestinal, Skin, and Reproductive System disorders.

Serious Safety Considerations and Restrictions

Regulatory documents explicitly list Serious Adverse Reactions, which include the risk of thromboembolic events, such as Pulmonary Embolism, and severe Anaphylactic Reactions. The product is subject to Safety-Related Restrictions and is formally contraindicated in specific situations, such as known or suspected malignancy of the breast or genital organs, a history of blood clots, or severe hepatic impairment. Population-specific safety notes state that Controlestril is contraindicated during pregnancy. Furthermore, duration-related safety patterns document that bone mineral density (BMD) loss is associated with the long-term use of the injectable formulation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Controlestril (Medroxyprogesterone Acetate) overdose is defined by specific documented manifestations and mandatory emergency response actions. Overdosage has been reported, with some high doses generally well-tolerated, however, immediate medical assessment is required in certain circumstances.

Documented Overdose Manifestations

Official labeling documents symptoms commonly associated with overdosage, including:

  • Nausea and Vomiting
  • Dizziness
  • Drowsiness or Fatigue
  • Abdominal Pain
  • Breast Tenderness
  • Withdrawal bleeding (may occur in women)

Required Emergency Actions

Regulatory authorities mandate that individuals seek emergency medical attention or call a poison control center immediately in the event of a suspected overdose. Urgent medical help is specifically required if the person exhibits severe symptoms such as seizure, collapse, trouble breathing, or cannot be awakened.

Official Management Strategy

Treatment for Medroxyprogesterone Acetate overdosage consists of discontinuing the medication and implementing appropriate symptomatic care and supportive treatment. Regulatory information states that no specific antidote is known for this compound, meaning management focuses entirely on addressing the clinical manifestations present.

Therapeutic Uses of Controlestril

What Controlestril Treats: Main Uses and Benefits

Controlestril (Medroxyprogesterone Acetate) is commonly used to manage specific clinical conditions and symptoms related to systemic imbalance, primarily within gynecological health and hormonal support. The application of the medication is relevant for providing symptomatic support in situations where hormonal regulation is needed. The medication is relevant for use across conditions involving recurrent or episodic manifestations.

Key indications where the medication is commonly used to help with include secondary amenorrhea, abnormal uterine bleeding (AUB), and the prevention of endometrial hyperplasia in postmenopausal women receiving estrogen therapy. It also may be part of symptomatic management for chronic pelvic pain associated with endometriosis. Controlestril helps support functional stability and a more predictable cycle pattern in cases of absent or erratic periods. This use contributes to improved comfort during periods of heightened symptoms and is relevant for easing the discomfort and strain of significant bleeding irregularities. Furthermore, it is considered relevant for easing vasomotor symptoms, such as disruptive hot flashes.

“This medicine is applied in contexts where additional management of discomfort is required, providing support that helps ease the overall symptom burden.”


Quick Fact: Relief for Menstrual Irregularities Controlestril is relevant for easing symptoms that interfere with daily comfort, particularly the unpredictability and distress linked to chronic abnormal uterine bleeding (AUB).

Eligibility and Restrictions for Use

Controlestril (Medroxyprogesterone Acetate) eligibility is strictly defined by regulatory documents, distinguishing approved populations from those who are absolutely prohibited from use. The medicine is generally allowed for adult women for approved indications and is indicated for adolescent females who have reached menarche.

Contraindicated Populations

Official labeling mandates that Controlestril must not be used by individuals with the following absolute contraindications:

  • Known or suspected pregnancy.
  • A current or past history of thromboembolic disorders (e.g., DVT, PE, stroke).
  • Known or suspected malignancy of the breast or other hormone-dependent cancers.
  • Significant liver disease or severe hepatic dysfunction.
  • Undiagnosed abnormal genital bleeding.
  • A history of hypersensitivity to Medroxyprogesterone Acetate.

Age and Condition-Specific Rules

  • Pediatric Use: The medicine is not indicated before menarche (the first menstrual period).
  • Geriatric Use: Use in postmenopausal women 65 and older receiving combination therapy with estrogen carries a specific warning regarding an increased risk of probable dementia.
  • Pregnancy and Lactation: Use during pregnancy is contraindicated. The medicine is detectable in breast milk; however, initiation is often advised only after the sixth week post-partum for exclusively breastfeeding mothers.

What should I know about interactions with other medicines?

Controlestril Interactions with other medicines and products

Interaction Scope

The official interaction profile for Controlestril (Medroxyprogesterone Acetate) is predominantly defined by pharmacokinetic modulation and specific pharmacodynamic effects. Medicinal product categories with documented interactions include Strong CYP3A Inhibitors, Strong CYP3A Inducers, and Estrogen-containing medicinal products.

The primary mechanistic basis for pharmacokinetic interactions is CYP3A4 enzyme modulation, as the medicine is principally metabolized via this pathway. Strong CYP3A Inducers (e.g., Rifampin, Phenytoin) are expected to decrease serum concentrations, which may reduce the medicine's effectiveness. The specific medicine Aminoglutethimide is documented to significantly depress MPA levels. Conversely, Strong CYP3A Inhibitors (e.g., Ketoconazole, Ritonavir) are expected to increase serum concentrations.

Interaction-Related Constraints

The herbal product St. John's wort is documented as an enzyme inducer that may decrease effectiveness. A documented pharmacodynamic interaction with Estrogens has been associated with a decrease in glucose tolerance in some patients. This requires a population-specific note: diabetic patients should be carefully observed during co-administration with estrogens. There are no mandatory timing-based separation requirements documented in the official labeling. Furthermore, Medroxyprogesterone Acetate may officially alter the results of certain laboratory tests, including those for coagulation factors and lipids.

Mechanism of Action

How Controlestril Works

Controlestril influences core biological mechanisms by acting selectively on defined molecular targets within key regulatory pathways. Its action is targeted and involves distinct phases of molecular and systemic modulation.

Controlestril's primary function is to serve as a selective modulator at the R X receptor system, which is part of the receptor- or enzyme-mediated signaling domain. By engaging this specific target, the molecule initiates a precise regulatory effect at the cellular level. This molecular action modifies the signaling sequences that lead to downstream effects, influencing the level of activity within the associated pathways.

After receptor binding, the mechanism proceeds by altering signaling dynamics in defined neural or humoral pathways. Controlestril engages mechanisms that influence feedback regulation within pathways by modifying the resulting intracellular cascade. This systemic adjustment results in an alteration of activity levels within targeted pathways, which influences the extent of excessive mediator activity, leading to subsequent physiological changes that constitute the drug's effect profile. This ultimately modulates the activity levels within associated systems, influencing the overall activity of processes driven by distinct signaling patterns.

Dosage and Administration Information

Official Administration Guidelines for Controlestril

Controlestril is administered via the oral route (by mouth). To ensure optimal efficacy, the tablet must be taken once daily at the same time every day, without skipping doses or allowing more than 24 hours between tablets. The daily dosing must follow the order directed on the blister pack.


Dosing and Preparation

Administration Scope Detail
Route of Administration Oral (Swallowing whole or chewing then swallowing).
Dosing Schedule One tablet daily for 28 consecutive days: 21 white active tablets followed by 7 peach inactive tablets.
Timing (Meals) On an empty stomach (without food).
Preparation If chewed, immediately swallow with a full glass of 240 mL water.
Special Conditions Start no earlier than 4 weeks after delivery in females who are not breastfeeding.

Missed Dose Instructions (Active Tablet)

Official guidelines provide specific steps for managing missed active tablets, depending on the number missed and the week they occur:

  • One active tablet missed (Weeks 1, 2, or 3): Take the missed tablet as soon as possible, even if it means taking two active tablets in one day. Continue taking one tablet a day until the pack is finished.
  • Two or more active tablets missed: The corrective procedure varies based on the starting regimen (Day 1 Start or Sunday Start) and the week of the pack. Generally, this requires taking the last missed tablet immediately and using a new pack, with nonhormonal contraception required for the subsequent 7 days.

For comprehensive missed-dose instructions and procedural steps for starting a new regimen (Day 1 Start or Sunday Start), refer directly to the product labeling.

Recent Clinical Evidence

Research Evidence for Controlestril

The clinical evaluation of Controlestril (Medroxyprogesterone Acetate) is based on studies reported in official regulatory sources and peer-reviewed scientific literature. This overview describes the research landscape for the medicine's main studied uses, focusing on the types of studies conducted and what remains uncertain.


Evidence for Regulating Absent or Irregular Menstrual Periods

Research has explored the use of Controlestril in premenopausal women with secondary amenorrhea (absent menstrual periods). Studies, which often included short-term, randomized controlled trials, focused on evaluating outcomes related to systemic or functional imbalance. Researchers examined the occurrence of a withdrawal bleeding event—an outcome related to physical discomfort—after a defined, short course of the active ingredient was completed.

Studies monitored how the uterine lining evolved during the trial period. Studies report how symptoms evolved in the observed populations, noting the occurrence of a bleeding event following the prescribed short treatment regimen. What is still uncertain is the long-term sustainability of the observed pattern, as follow-up durations were limited in these core studies.


Evidence for Managing Abnormal Uterine Bleeding

Controlestril was studied for use in conditions associated with acute or disruptive episodes, specifically Abnormal Uterine Bleeding (AUB). Research examined short-term symptom patterns in women of reproductive age through randomized and comparative trials. The primary outcomes examined were outcomes describing episodic or acute changes such as bleeding cessation, and the subsequent pattern of menstrual cycles.

Comparative trials findings describe patterns observed in the studies related to bleeding cessation. A key limitation is that high-quality, placebo-controlled evidence is lacking for acute AUB, as comparative evidence is lacking in many settings due to ethical challenges. Therefore, certainty remains low regarding the absolute effect over no treatment.


Evidence for Protecting the Uterine Lining

Studies examining the prevention of endometrial hyperplasia (over-thickening of the uterine lining) was evaluated in large-scale, long-term randomized controlled trials. Research describes data showing patterns related to changes in the incidence of endometrial hyperplasia when the active ingredient was added to estrogen therapy compared to women receiving unopposed estrogen.

It is important to note that the research structure specifically evaluates the compound as part of a combination hormone therapy; data for its use as a standalone preventive agent for this purpose in this specific population are not the focus of these core studies.

Frequently Asked Questions (FAQ)

Common questions about Controlestril (FAQ)

Q: Is Controlestril the same kind of medication as [Similar Drug Name]?

Controlestril contains Medroxyprogesterone Acetate (MPA), which is classified as a synthetic steroid and belongs to a category of medicines called progestins. While other medications may share this general classification, they can still differ in their specific chemical structure, strength, or authorized uses. Official information defines the drug primarily by its active ingredient and its general mechanism as a progestin.

Q: How quickly does Controlestril usually start working?

Official information indicates that the tablets may begin their action immediately after administration. However, for a noticeable pattern of the full intended effect to emerge—such as changes in menstrual patterns—it may take approximately two to three months. The timing can vary based on the condition being addressed and individual response.

Q: How long can a person stay on Controlestril treatment?

For gynecological issues like regulating periods, treatment often involves short courses, typically over a few months. For any proposed long-term use (e.g., exceeding two years) in certain settings, specific safety evaluations are noted in regulatory information when use is extended for a long period. This is due to potential regulatory warnings regarding effects on bone mineral density associated with extended use.

Q: Does Controlestril have an official Black Box Warning from the FDA?

The injectable form of the medicine’s active ingredient is subject to an official FDA Boxed Warning. This warning highlights the potential for bone mineral density loss that may occur with increasing duration of use. The full prescribing information contains complete details regarding this safety consideration.

Q: Can Controlestril be taken by older adults (e.g., over 65)?

Official resources note that the medicine should be used with care in individuals aged 65 and older, as there may be an increased likelihood of side effects. Additionally, postmenopausal women in this age group who are receiving combination hormone therapy have a specific safety note regarding a potential increased risk of probable dementia.

Q: Are there any common foods or drinks to avoid when taking Controlestril?

The medicine is prescribed to be taken on an empty stomach, as specified in administration guidelines. While there is no list of common foods or specific beverages that are strictly prohibited, some patient information advises that consuming a high amount of alcohol should be avoided during the administration of the medicine.

Q: Is Controlestril available in generic form?

Yes, the active ingredient in Controlestril, Medroxyprogesterone Acetate, is available in generic tablet form in certain regions. This generic option is available in addition to the branded version.

Q: Is it normal to feel a change in energy levels after starting Controlestril?

Fatigue and feeling tired are documented as common side effects in official safety information. General changes in energy levels or feelings of weakness are among the potential effects noted in regulatory reports on the medicine.

Q: Can Controlestril cause issues with sleep?

Official adverse reaction lists document that the medicine may affect sleep patterns. Both difficulty falling or staying asleep (insomnia) are listed as common effects, and excessive sleepiness (somnolence) is listed as an uncommon effect.

Q: What is the risk of dependence or withdrawal associated with Controlestril?

Official labeling notes that a specific event called progestin withdrawal bleeding is noted in labeling to occur, typically within three to seven days after discontinuing the medicine when used to regulate the menstrual cycle. Regulatory information does not address concerns about dependence on the medication.

Q: Are there any documented interactions between Controlestril and alcohol?

While a formal pharmacokinetic interaction is not documented in the medicine’s core interaction profile, official patient information advises that the consumption of high amounts of alcohol should be avoided during the administration of the medicine.

Q: Does Controlestril affect blood pressure readings?

An increase in blood pressure has been reported as an adverse reaction in association with progestin therapy. For individuals with conditions influenced by fluid retention, careful observation is noted in the labeling.

Q: Does Controlestril affect fertility in men or women?

Regulatory information indicates that the medicine may temporarily reduce fertility while it is being used by women. Official information indicates that fertility returns after the medicine is stopped, though the exact timing can vary.

Q: Why is Controlestril not recommended for people with a history of heart conditions?

The medicine is strictly contraindicated (absolutely prohibited) for individuals with a history of thromboembolic disorders, which are conditions involving blood clots. Furthermore, due to the potential for progestin therapy to cause fluid retention, caution is noted in official documents for patients with conditions such as cardiac dysfunction.

Q: What is the typical time frame to evaluate if Controlestril is working?

Official guidance notes that while the medicine may start its action right away, it can take approximately two to three months for the full intended therapeutic effect to be observed. Assessment of the medicine's effectiveness is based on the specific condition it was prescribed to address.

Q: Can Controlestril be crushed or split if a person has trouble swallowing?

Official administration guidelines for the oral tablet describe its use by either swallowing it whole or by chewing it before swallowing with a full glass of water. This refers to the accepted administration routes as described in the product labeling.

Q: How is Controlestril processed and removed from the body?

The medicine is processed within the body primarily by the liver through a specific enzyme system called CYP3A4. This enzymatic process is the primary route for the medicine’s chemical breakdown and elimination from the body.

Q: Are there official warnings about operating heavy machinery while using Controlestril?

Official product information notes that caution should be exercised regarding driving or operating heavy machinery until an individual is aware of how the medicine affects them. This warning is due to the potential for side effects, such as dizziness or sleepiness.

Q: What is the general advice for people who feel dizzy after taking Controlestril?

Regulatory resources include general recommendations for managing dizziness, which suggest stopping the current activity and sitting or lying down until the feeling lessens. Official safety warnings advise against driving or using tools or machinery if dizziness is present.

Q: Are there any genetic factors that affect how Controlestril works?

Scientific research has examined genetic factors, such as the Estrogen Receptor (ESR), that may be related to how the drug’s active ingredient functions in the body. However, official documents do not provide specific, individualized patient guidance based on these complex genetic factors.

How should Controlestril be stored and disposed of?

Controlestril must be stored strictly according to the conditions described on the official product label to maintain its stability and effectiveness. The label specifies the exact temperature, such as Room Temperature (e.g., up to 25 C or 30 C) or Refrigerated left(2 C - 8 C ight), and may require protection from moisture or light. Always keep the product in its original container and securely out of the reach of children and pets.

As a controlled substance, Controlestril has specific disposal requirements to prevent misuse or diversion. Do not dispose of this medication by flushing it down a toilet or pouring it down a drain. Unused or expired medication should be destroyed promptly through an authorized method, such as a drug take-back program or by delivering it to an authorized collector, to ensure it is rendered non-retrievable. Consult local regulations or your pharmacy for disposal locations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Controlestril found in:

A-Z Index: